Please login to the form below

Not currently logged in
Email:
Password:

PCSK9

This page shows the latest PCSK9 news and features for those working in and with pharma, biotech and healthcare.

Regeneron scores positive data in phase 3 cholesterol trial

Regeneron scores positive data in phase 3 cholesterol trial

Despite patients already taking lipid-lowering treatments, such as statins and PCSK9 inhibitors, their levels of cholesterol remained dangerously high prior to enrolment in the study. ... Regeneron and partner Sanofi have another approved

Latest news

More from news
Approximately 16 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    With the partners gearing up to launch Amgen's PCSK9 therapy for hypercholesterolemia - a class of drugs that is top of many peoples' minds - it's an approach that seems to

  • Pharma deals in September 2015 Pharma deals in September 2015

    Amgen's busy month (part 2). Following FDA approval for its novel PCSK9 treatment for “bad cholesterol”, Amgen is moving onto tackle dyslipidemia, an asymptomatic disease in which serum lipid levels

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration

  • Pharma deals during November 2014 Pharma deals during November 2014

    In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9 inhibitor alirocumab, being developed in partnership with Sanofi.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics